Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients
Seminars in Arthritis and Rheumatism, Volume 45, No. 3, Year 2015
Notification
URL copied to clipboard!
Description
Objectives: To assess anti-TNF-α therapy response in uveitis associated with sarcoidosis refractory to conventional immunosuppressive therapy. Methods: Open-label, multicenter, retrospective study on patients with sarcoid uveitis who underwent anti-TNF-α therapy because of inadequate response to conventional therapy including corticosteroids and at least 1 systemic synthetic immunosuppressive drug. The main outcome measurements were degree of anterior and posterior chamber inflammation, visual acuity, macular thickness, and immunosuppression load. Results: A total of 17 patients (8 men; 29 affected eyes; mean ± standard deviation age 38.4 ± 16.8; range: 13-76 years) were studied. The patients had bilateral hilar lymphadenopathy (58.8%), lung parenchyma involvement (47.1%), peripheral lymph nodes (41.2%), and involvement of other organs (52.9%). Angiotensin-converting enzyme was elevated in 58.8%. The most frequent ocular pattern was bilateral chronic relapsing panuveitis. The first biologic agent used was adalimumab in 10 (58.8%) and infliximab in 7 (41.2%) cases. Infliximab 5 mg/kg intravenously every 4-8 weeks and adalimumab 40 mg subcutaneously every 2 weeks were the most common administration patterns. In most cases anti-TNF-α therapy was given in combination with immunosuppressive drugs. The mean duration of follow-up was 33.9 ± 17.1 months. Significant improvement was observed following anti-TNF-α therapy. Baseline results versus results at 2 years from the onset of biologic therapy were the following: the median of cells in the ocular anterior chamber (interquartile range. -IQR) 0.5 (0-2) versus 0 (0-0) (p = 0.003), vitritis 0 (0-1.25) versus 0 (0-0) (p = 0.008), macular thickness (391.1 ± 58.8 versus 247 ± 40.5 μm) (p = 0.028), and visual acuity 0.60 ± 0.33 versus 0.74 ± 0.27; p = 0.009. The median daily (interquartile range) dose of prednisone was also reduced from 10 (0-30). mg at the onset of the anti-TNF-α therapy to 0 (0-0). mg at 2 years (p = 0.02). Significant reduction was also achieved in the immunosuppressive load. Conclusion: Anti-TNF-α therapy is effective in sarcoid uveitis patients refractory to conventional immunosuppressive therapy. Infliximab and adalimumab allowed a substantial reduction in prednisone dose despite having failed standard therapy. © 2015 Elsevier Inc.
Authors & Co-Authors
Riancho-Zarrabeitia, Leyre
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Calvo-Río, Vanesa
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Blanco-Alonso, Ricardo
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Mesquida Febrer, Marina
Spain, Barcelona
Hospital Clinic Barcelona
Adán, Alfredo Manuel
Spain, Barcelona
Hospital Clinic Barcelona
Peiteado, Diana
Spain, Madrid
Hospital Universitario la Paz
Cordero-Coma, Miguel
Spain, Leon
Hospital de León
Ortego-Centeno, Norberto
Spain, Granada
Hospital Universitario San Cecilio
Maíz Alonso, Olga
Spain, Donostia-san Sebastian
Osakidetza, Donostia University Hospital
González-Suárez, Senén
Spain, Gijon
Hospital de Cabuenes
Fonollosa, Alex
Spain, Baracaldo
Osakidetza, Cruces University Hospital
González-Vela, María Carmen
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Loricera, Javier
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Piña, Trinitario
Spain, Santander
Hospital Universitario Marqués de Valdecilla
González-Gay, Miguel Ángel
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Statistics
Citations: 67
Authors: 15
Affiliations: 11
Identifiers
Doi:
10.1016/j.semarthrit.2015.05.010
ISSN:
00490172
Study Design
Cohort Study
Participants Gender
Male